Uveitis Drug Pipeline Analysis Report 2024

Report Coverage

The Uveitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into uveitis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Uveitis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The uveitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from uveitis.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to uveitis.

Uveitis Drug Pipeline Outlook

Uveitis refers to an inflammatory disease that involves inflammation of the middle layer of the eye called uvea. The disease can be caused due to infections, idiopathic cases, trauma, and inflammatory diseases. The symptoms can range from redness, pain, and blurry vision to complete vision loss, indicating that prompt treatment is essential to prevent severe complications. Anterior uveitis ranks as the most prevalent type of the condition, comprising nearly 50% of all uveitis cases, whereas posterior uveitis is reported as the least common form.

Treatment for uveitis depends on the underlying cause of the disease. Symptom-based treatments typically focus on pain control, inflammation reduction (steroids and nonsteroidal anti-inflammatory drugs (NSAIDs)), and condition-specific treatments. There is an increased emphasis on developing biologic drugs that target specific inflammatory pathways and new classes of small-molecule inhibitors, such as JAK inhibitors, in order to expand treatment options. Further, the rising investment in ophthalmic drug development and advancements in drug delivery technologies are driving the uveitis drug pipeline forward with several highly promising candidates in clinical development.

Uveitis – Drug Pipeline Therapeutic Assessment

Uveitis – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for uveitis. There are around 109 drugs in phase II for uveitis.

Uveitis – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under uveitis pipeline analysis are corticosteroids, immunosuppressants/immunomodulators, biologic agents, anti-TNF agents, interleukin inhibitors, jak inhibitors, calcineurin inhibitors, anti-VEGF agents, antibiotics and antivirals, and small-molecule inhibitors. The choice of treatment depends on multiple factors including the underlying inflammation and the immune response involved in the condition.

Uveitis Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the uveitis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uveitis clinical trials:

• Eli Lilly and Company
• Priovant Therapeutics, Inc.
• Bio-Thera Solutions
• ACELYRIN Inc.
• AbbVie
• Allergan
• Lux Biosciences, Inc.
• Novartis Pharmaceuticals
• Amgen

Uveitis – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Brepocitinib

Sponsored by Priovant Therapeutics, Inc., brepocitinib is a selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor that is being investigated in a Phase 3 clinical trial with around 220 participants having active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

QLETLI

QLETLI (Adalimumab Injection), Bio-Thera's biosimilar to Humira® is undergoing a Phase 4 post-marketing clini...

Izokibep

Izokibep is in a Phase 2 study to evaluate its clinical activity against treating active non-infectious, inter...

Laquinimod eye drops

Currently, in Phase 1 of a prospective, single-center phase 1 clinical study, Laquinimod eye drops are under i...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Reasons To Buy This Report

The Uveitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for uveitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within uveitis pipeline insights.

Key Questions Answered in the Uveitis – Pipeline Insight Report

• What is the current landscape of uveitis pipeline drugs?
• How many companies are developing uveitis drugs?
• How many phase III and phase IV drugs are currently present in uveitis pipeline drugs?
• Which companies/institutions are leading the uveitis drug development?
• What is the efficacy and safety profile of uveitis pipeline drugs?
• What are the opportunities and challenges present in the uveitis drug pipeline landscape?
• Which company is conducting major trials for uveitis drugs?
• What geographies are covered for uveitis clinical trials?
• What are emerging trends in uveitis clinical trials?

Related Reports

Global Uveitis Drugs Market

Global Clinical Trials Market